TET2 and chronic myelomonocytic leukemia: SMITH et al (2010) [12] reported that TET2 mutations had no prognostic value for patients with MDS and CMML and Kim et al (2015) [20] indicated that TET2 mutations were a poor prognostic factor in patients with MDS.